Adalimumab Induced Aseptic Meningitis and Focal Partial Seizures in Patient with Crohn’s Disease

Corey S. Ellis¹, Hayden L. Smith¹*, Lisa A Veach²

¹Graduate Medical Education, UnityPoint Health-Des Moines, Des Moines, United States
²UnityPoint Clinic Multi-Specialty-Infectious Disease, UnityPoint Health, Des Moines, United States
*Corresponding author: hayden.smith@unitypoint.org

Received July 14, 2019; Revised August 18, 2019; Accepted September 01, 2019

Abstract  Tumor necrosis factor α inhibitors (TNFα-i) are a commonly prescribed class of medications for the treatment of inflammatory bowel disease. With the increasing use of this medication class, some uncommon adverse effects have been reported. We present a case of a young male recently prescribed adalimumab for Crohn’s disease who developed aseptic meningitis with associated focal partial seizures.

Keywords: anti-inflammatory agents/adverse effects, crohn disease/drug therapy, adalimumab, meningitis, aseptic/chemically induced, meningitis, aseptic/drug therapy

Cite This Article: Corey S. Ellis, Hayden L. Smith, and Lisa A Veach, “Adalimumab Induced Aseptic Meningitis and Focal Partial Seizures in Patient with Crohn’s Disease.” American Journal of Medical Case Reports, vol. 7, no. 11 (2019): 289-291. doi: 10.12691/ajmcr-7-11-7.

1. Introduction

Tumor necrosis factor α inhibitors (TNFα-i) are an increasingly prescribed class of medications for the treatment of inflammatory bowel disease. Their use in the treatment of Crohn’s disease was first approved by the US Food and Drug Administration (FDA) in 1998. The latest American Gastroenterology Association guidelines on the treatment of Crohn’s disease listed TNFα-i as a primary medication class to induce and maintain symptom remission. [1] With increasing use of this medication class, some uncommon adverse effects, including aseptic meningitis, have been reported. The first case of TNFα-i induced aseptic meningitis (TAAM) was published in 2001. [2] To date, there have been 13 published cases describing the correlation between TNFα-i and aseptic meningitis. [3,4,5] Presented is a case report on a young male recently prescribed adalimumab for Crohn’s disease who developed aseptic meningitis with associated focal partial seizures.

2. Case

A 24-year-old male presented to the Emergency Department (ED) with acute onset right-sided headache with left-sided paresthesia. The patient reported left facial droop and two episodes of left-sided weakness and numbness, each lasting 15 minutes before spontaneous resolution. These weaknesses started distally in his toes and fingers and migrated proximally. He did not have complete paralysis. The patient’s past medical history was significant for a recent diagnosis of Crohn’s disease. He had received his third dose of adalimumab (i.e., dosed every two weeks) 12 days prior to his presentation. Surgical history and family history were non-contributory. The patient denied tobacco, ethanol, or drug use, and was currently employed as a service technician.

The patient was admitted for further evaluation. Head computed tomography scan and computed tomography angiography of head/neck were both unremarkable. Electroencephalogram was normal. Cluster headaches were suspected, and the patient was discharged home on day two with a prescription for sumatriptan.

The day after discharge the patient had a third episode of acute onset right-sided headache with left-sided weakness that was unresponsive to sumatriptan, prompting his return to the ED. Patient’s vitals included temperature 100 F°, blood pressure 179/93 mmHg, pulse 74 beats/minute, respiratory rate 16 breaths per minute, and oxygen saturation 94%. His neurologic exam was normal. Laboratory studies were also normal including: serum white blood cell count of 8.6 x 10³/µL (i.e., 49% neutrophils, 36% lymphocytes), hemoglobin 16.3 g/dl, sodium 135 mEq/L, potassium 3.6 mEq/L, chloride 99 mEq/L, bicarbonate 26 mEq/L, BUN 14 mg/dL, creatinine 1.10 mg, glucose 105 mg/dL, and calcium 9.8 mg/dL.

The patient was re-admitted. Neurology was consulted, and another electroencephalogram was conducted revealing rhythmic and semi-rhythmic delta waves in the right frontotemporal region. A second head/neck computed tomography angiography was conducted and failed to show vasospasm. Magnetic resonance imaging of brain with contrast was normal. A lumbar puncture was performed with findings presented in Table 1.
Symptomatic treatment was initiated with diphenhydramine, metoclopramide, and toradol. No antibiotics were started. An Infectious Disease consult was requested. Patient denied travel history, freshwater exposure, or tick/mosquito exposure. Last sexual contact was six months ago. Additional cerebrospinal fluid (CSF) testing was negative including cerebrospinal fluid film array and polymerase chain reaction (PCR) panel for pathogens. Pathogens tested for included bacteria (i.e., Escherichia coli K1, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitides, Streptococcus agalactiae, Streptococcus pneumoniae, Borrelia burgdorferi), viruses (i.e., cytomegalovirus, enterovirus herpes simplex virus 1, herpes simplex virus 2, human herpesvirus 6, human parechovirus, varicella zoster virus, West Nile virus), fungi (i.e., Cryptococcus neoformans/gattii)); and oligoclonal bands. All cultures (bacterial, fungal, and acid-fast bacilli) were negative. Additional serum testing was also negative: paraneoplastic autoantibody panel (acetyl receptor bind antibody, antiglial nuclear antibody, amphiphisyn, ANNA-3, anti-neuronal nuclear antibody type 1 and 2, CRMP-5-IgG, N-type calcium channel antibody, neuronal potassium channel antibody, P/Q Type calcium channel antibody, Purkinje cell antibody (PCA) type 1 and 2, PCA-Tr, striational antibody), hepatitis C antibody, HIV 4th generation, syphilis IgG, and lymphocytic choriomeningitis antibody.

Given the clinical and CSF findings, TAAM with Jacksonian march seizures due to adalimumab was suspected to be the cause of symptoms. Adalimumab was discontinued, and the patient was discharged home in stable condition. At the patient’s last gastroenterologist follow-up appointment, he remained off TNFα-i for one and a half years after his initial presentation to ED. Six months later at the patient’s last visit with his primary care provider, it was stated he had no new or recurrent neurologic symptoms as of two years after his initial presentation. The presented study of a single patient was approved by the local Institutional Review Board of record and received a waiver of consent.

3. Discussion

With the increased use of TNFα-i, general knowledge of both common and uncommon adverse drugs effects is important. Commonly described side effects are headache, fever, infection, arthralgia, and rash. [6] TNFα-i aseptic meningitis (TAAM) is a rare but potentially serious side effect with an increasing number of reports. Most of these patients presented with fever and meningeval signs. Although most cases describe mild symptoms with resolution within 24 hours, [7] one prior case demonstrated TAAM as being fatal. [8]

The pathophysiology of TAAM remains unclear. It has been hypothesized that the mechanism is a type III hypersensitivity reaction akin to serum sickness. [7] Another proposed mechanism is an altered cytokine milieu resulting from peripheral inhibition of TNFα-i, which then upregulates pro-inflammatory pathways in the brain of susceptible individuals. [2] Direct drug toxicity to the brain is not considered a viable mechanism due to its inability to cross the blood brain barrier. [3]

Since the first report of TAAM was published in 2001, [2] several other cases have now been published. [3,4,5] In addition, other, even less common, neurologic manifestations have been reported including: Guillain-Barre, [9] multiple sclerosis, [10] optic neuritis, [11,12] demyelinating encephalomyelitis, [13] and mononeuritis multiplex. [14] While most patients with TAAM had normal neurologic exams, some did have objective lower extremity weakness [9] or positive Kernig/Brudzinski signs. [6] To date, there has been only one other case report of seizure activity related to TNFα-i. [8] The publication reported a patient with generalized seizure. To the authors’ knowledge, this is the first case of a patient presenting with aseptic meningitis with focal partial seizures while on adalimumab.

A pertinent clinical question is whether a patient that developed TAAM should be re-trialed on the medication. In one case report, severe activity associated with Crohn’s disease led to resumption of TNFα-i therapy. [15] Authors of the report noted no recurrence of the adverse reaction despite resuming the same medication. However, the time frame for re-introduction of the medication was unclear in the article. In the presented case report, due to safety, the reintroduction of TNFα-i therapy was not assessed since the patient’s Crohn’s disease has remained controlled when off TNFα-i therapy. Further research in this area is needed to better understand and study this topic.

In summary, the presented case describes the first reported patient to date who developed aseptic meningitis complicated by focal partial seizures in association with administration of adalimumab for treatment of Crohn’s disease. More research is needed to determine if a patient can safely resume the class of medication after experiencing a severe adverse event. This will become an important question to answer as TNFα-i is increasingly prescribed. It is also important that gastroenterologists provide patient education on rare but significant side effects.

Acknowledgements

There are no acknowledgements.

Disclosures

The authors have no competing interests.
Abbreviations

TNFα-i: tumor necrosis factor α inhibitors
TAAM: TNFα-i induced aseptic meningitis.

References

[1] Terdiman, J.P., Gruss, C.B., Heidelbaugh, J.J., Sultan, S., Falck-Ytter, Y.T. “American Gastroenterological Association Institute Guideline on the use of thiopurines, methotrexate and anti-TNF-alpha biologic drugs for induction and maintenance of remission in inflammatory Crohn’s disease.” Gastroenterology, 145: 1459-63. Dec. 2013.

[2] Marotte, H., Charrin, J.E., Miossec, P. “Infliximab-induced aseptic meningitis.” Lancet, 358: 1784. Nov. 2001.

[3] Wang, D.Y., Chong, W.S., Pan, J.Y., Heng, Y.K. “First case report of aseptic meningitis induced by adalimumab administered for treatment of chronic plaque psoriasis.” J Investig Allergol Clin Immunol, 27: 183-5. Feb. 2017.

[4] Hamilton, A.J., Gutowski, N.J. “Aseptic meningitis in a patient receiving treatment with anti-tumour necrosis factor alpha.” J Neurol, 258: 1174-5. Dec. 2011.

[5] Matsurra-Otsuki, Y., Hanafusa, T., Yokozeki, H., Watanabe, K. “Infliximab-induced aseptic meningitis during the treatment of psoriatic arthritis.” Case Rep Dermatol, 9: 26-9. May 2017.

[6] Shah, R., Shah, M., Bansal, N., Manocha, D. “Infliximab-induced aseptic meningitis.” Am J Emerg Med, 32: 1560. e3-4. 2014.

[7] Hegde, N., Gayomali, C., Rich, M.W. “Infliximab-induced Headache and Infliximab-induced meningitis: Two ends of the same spectrum?” South Med J, 98: 564-6. Oct. 2005.

[8] Quispel, R., van der Worp, H.B., Pruijssen, M., Schipper, M.E., Oldenburg, B. “Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease.” Gut, 55: 1056. 2006.

[9] López Méndez, P., Martín Santana, I., del Pino Reyes Yáñez, M., Ruano Hernandez, A., Hernandez Beriaín, J.A., Hervas Garcia, M. “Meningeal and Guillain–Barrè syndrome in a patient with rheumatoid arthritis receiving adalimumab therapy.” Reumatol Clin, 7: 401-3. 2011.

[10] Honda, Y., Otsuka, A., Egawa, G., Inoue, Y., Kuzuya, A., Takahashi, R., Miyachi, Y., Kabashima, K. “Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-α therapy in psoriatic arthritis.” Eur J Dermatol, 25: 487-8. 2015.

[11] Simsek, I., Erdem, H., Pay, S., Sobaci, G., Dinc, A. “Optic neuritis occurring with anti-tumour necrosis factor α therapy. Ann Rheum Dis, 66: 1255-8. 2007.

[12] Chung, J.H., Van Stavern, G.P., Frohman, L.P., Turbin, R.E. “Adalimumab-associated optic neuritis.” J Neurol Sci, 244: 133-6. 2006.

[13] Sillero Sánchez, M., García Domínguez, G., Asencio Marchante, J.J. “Demyelinating encephalomyelitis associated with treatment with adalimumab.” Neurologia (English Edition), 25: 136-8. 2010.

[14] Makol, A., Grover, M. “Adalimumab induced mononeuritis multiplex in a patient with refractory rheumatoid arthritis: A case report.” Cases J, 1: 287. 2008.

[15] Manthey, C., Lohse, A.W., Pace, A. “Case report of aseptic meningitis in a patient with Crohn’s disease under infliximab therapy.” Inflamm Bowel Dis, 17: E10. Feb. 2011.